ResonanceDx, Inc. is a Point-of-Care diagnostic device startup company. Our novel, flexible testing platform can provide rapid results to support immediate clinical decision-making.
The ResonanceDx
platform uses highly sensitive Bulk Acoustic Resonance Sensing (BARS*) to rapidly measure binding of antigens to antibodies in real time with no sample preparation, reagents, or lasers.
*US Patents 9,473,106 and 8,810,108
US Patent pending 14/759,078 and others
Wafer of ResonanceDx Sensors
Silicon wafer fabrication of sensor arrays makes scaling of manufacturing inexpensive
The technology detects shifts in resonant frequencies of antibodies bound to piezoelectric resonators.
News:
ResonanceDx, Inc recently placed in the Final Five Finalists of the 2021 Cade Prize.
Carlos Moreno interviewed by the Radio Cade Podcast.
Carlos Moreno interviewed by CEOCFO Magazine.